BioNexus Gene Lab Insider Trades
NASDAQ: BGLCHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
BioNexus Gene Lab insider activity
Over the last 12 months, BioNexus Gene Lab insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Tan Lee Su-Leng (Chief Executive Officer) reporting a transaction in 338,709 shares on Aug 13, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put BGLC's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
BGLC insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 13, 2026 | Low Jook YuenDirector | Award | 16,129 | — | Form 4 |
| Aug 13, 2026 | Chong Set FuiChief Financial Officer | Award | 96,774 | — | Form 4 |
| Aug 13, 2026 | Yap Chee KeongDirector | Award | 32,258 | — | Form 4 |
| Aug 13, 2026 | Bin Abdul Hamid Muhammad AzrulDirector | Award | 32,258 | — | Form 4 |
| Aug 13, 2026 | Tan Lee Su-LengChief Executive Officer | Award | 338,709 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4